Bristol-Myers Squibb Services Unlimited Company

Oncology

The sponsor’s oncology portfolio spans non-small cell lung cancer, melanoma, urothelial cancer, breast cancer, colorectal cancer, pancreatic ductal adenocarcinoma, gastric and gastroesophageal cancers, hepatocellular carcinoma, renal cell carcinoma, ovarian cancer, bladder cancer, and myelofibrosis. It also includes studies in acute myeloid leukemia, myelodysplastic syndrome, primary central nervous system lymphoma, and other advanced solid tumors.

  • Immuno-oncology
  • Targeted therapy
  • Metastatic cancer
  • Hematologic malignancies
  • Perioperative and first-line cancer treatment

Research activity includes treatment of EGFR-mutated and KRAS G12C-mutant disease, as well as platinum-resistant and unresectable cancer settings.

Autoimmune and inflammatory disease

Clinical research in immune-mediated disease centers on systemic lupus erythematosus, cutaneous lupus erythematosus, psoriatic arthritis, plaque psoriasis, rheumatoid arthritis, Sjögren’s syndrome, systemic sclerosis, idiopathic inflammatory myopathy, ulcerative colitis, and atopic dermatitis.

  • Systemic lupus erythematosus
  • Psoriatic arthritis
  • Psoriasis
  • Inflammatory bowel disease
  • Connective tissue disease

Additional work extends to juvenile psoriatic arthritis and pediatric immune-mediated conditions.

Neurology and psychiatry

The sponsor funds trials in Alzheimer’s disease, including early and mild to moderate stages, with associated agitation and psychosis. Its neuroscience portfolio also includes bipolar I disorder, mania, schizophrenia, and relapsing remitting multiple sclerosis.

  • Alzheimer’s disease
  • Bipolar I disorder
  • Schizophrenia
  • Multiple sclerosis
  • Neuropsychiatric symptoms

Research also addresses primary central nervous system lymphoma within the broader neuro-oncology landscape.

Pulmonary and cardiovascular disease

Respiratory and cardiometabolic studies include idiopathic pulmonary fibrosis, progressive pulmonary fibrosis, and heart failure with preserved ejection fraction. Cardiovascular research also covers symptomatic obstructive hypertrophic cardiomyopathy.

  • Interstitial lung disease
  • Pulmonary fibrosis
  • Heart failure
  • Hypertrophic cardiomyopathy

These programs reflect interest in chronic cardiopulmonary disorders with significant unmet treatment need.

Hematology, transplantation, and rare disease

Additional clinical work includes sickle cell disease, renal transplantation, and adolescent renal allograft care, alongside studies in myelofibrosis and other hematologic disorders. The portfolio also extends to urothelial carcinoma and solid malignancies with high-risk or refractory features.

  • Sickle cell disease
  • Renal transplantation
  • Myelofibrosis
  • Urothelial carcinoma

Research activity in these areas spans both chronic disease management and oncology-linked rare conditions.

Want to learn more about this study or check if you can participate? Contact us.

Matched clinical trials

  • Pumitamig Versus Pembrolizumab in Patients With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%

    Recruiting

    3 1 1 1
    Investigated drugs:
    Austria Belgium Bulgaria Czechia Finland France +10
  • Pumitamig Versus Durvalumab in Patients With Unresectable Stage III Non-Small Cell Lung Cancer Without Progression After Chemoradiation

    Recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Austria Belgium Bulgaria France Germany Greece +8
  • A Study of BMS-986504 Combined with Nab-Paclitaxel and Gemcitabine for Patients with Untreated Metastatic Pancreatic Cancer with MTAP Gene Deletion

    Recruiting

    4 1 1
    Austria Belgium Czechia Denmark France Germany +9
  • A Study of BMS-986517 for Adults with Advanced Solid Tumors to Test Safety and Find the Best Dose

    Recruiting

    2 1 1
    Denmark Spain
  • Study of trospium chloride and xanomeline tartrate combination for agitation in Alzheimer’s disease patients: Long-term safety evaluation

    Recruiting

    3 1 1
    Bulgaria Croatia Czechia France Greece Hungary +5
  • Study on the Effectiveness and Safety of Deucravacitinib for Patients with Active Systemic Lupus Erythematosus (SLE)

    Recruiting

    3 1
    Investigated diseases:
    Investigated drugs:
    Bulgaria Czechia Greece Hungary Poland Portugal +1